An Australian stem cell and regenerative medicine company

January 16, 2020

Shaw and Partners Flashnote: “UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw and Partners Research Update for Cynata Therapeutics



December 17, 2019

H.C. Wainwright & Co. Company Update: “Preclinical Sepsis Data Hint at Therapeutic Potential; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics

December 10, 2019

Shaw and Partners Flash Note: “Positive News Flow Continues to Support Outlook; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

October 18, 2019

Shaw and Partners Flash Note: “Cynata and Sumitomo Withdraw from Acquisition Discussions; ‘Buy’ Rating; Price Target $3.00

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

September 20, 2019

Shaw and Partners Research Update September 19, 2019: “Fujifilm Takes Up its GvHD License Option Providing Commercial Validation of CYP’s Platform”; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics